Expand all sections

Semaglutide

Wegovy

Extended indication Extension of indication to include treatment of adolescents for weight management for Wegovy.
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Semaglutide
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension
Main indication Other metabolism and Endocrinology
Extended indication Extension of indication to include treatment of adolescents for weight management for Wegovy.
Proprietary name Wegovy
Manufacturer Novo Nordisk
Mechanism of action GLP-1 receptor agonist
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date September 2022
Expected Registration July 2023
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet
Duration of treatment Average 68 week / weeks
Frequency of administration 1 times a week
Dosage per administration 2,4 mg
References Weghuber et al 2022 NEJM
Additional remarks In combinatie met leefstijl interventie. De behandelduur was de maximale behandelduur in de studie.

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.